Acute myocardial infarction following erlotinib treatment for NSCLC: A case report

作者：Ding, Shanshan; Long, Fei; Jiang, Shujuan^*

来源：Oncology Letters, 2016, 11(6): 4240-4244.

DOI：10.3892/ol.2016.4508

• lung cancer
• targeted therapy
• erlotinib
• adverse reactions
• myocardial infarction

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted anticancer drug that is used to treat non-small cell lung cancer (NSCLC). Previous studies have confirmed that erlotinib is safe and is well-tolerated by patients. The most common adverse reactions observed following erlotinib treatment include a rash and mild diarrhea. In the current study, the first case of acute myocardial infarction following one month of treatment with erlotinib in a 63-year-old male NSCLC patient is presented. The present study highlights the importance of clinicians remaining cautious following erlotinib administration. In elderly NSCLC patients and those with a history of coronary heart disease, cardiac function must be carefully monitored following erlotinib treatment so that serious adverse reactions, such as myocardial infarction, may be identified early and treated quickly.

• 出版日期2016-6
• 单位山东大学